China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021
February 14, 2022 at 09:01 am EST
Share
China Health Industries Holdings, Inc. reported earnings results for the second quarter and six months ended December 31, 2021. For the second quarter, the company reported sales was USD 0.000002 million compared to USD 3.09 million a year ago. Net loss was USD 0.573524 million compared to net income of USD 0.816043 million a year ago. Basic loss per share from continuing operations was USD 0.0088 compared to basic earnings per share from continuing operations of USD 0.0125 a year ago.
For the six months, sales was USD 0.000268 million compared to USD 5.28 million a year ago. Net loss was USD 0.594911 million compared to net income of USD 1.46 million a year ago. Basic loss per share from continuing operations was USD 0.0091 compared to basic earnings per share from continuing operations of USD 0.0222 a year ago.
China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.
CHINA HEALTH INDUSTRIES HOLDINGS, INC. 
